OpGen, Inc.

153 articles with OpGen, Inc.

• OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections

  4/19/2021

  Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021 Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions

• OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients

  4/12/2021

  Experts presented the results of their Unyvero studies and demonstrated: Distinguishing those COVID-19 ICU patients with bacterial superinfection early and accurately is crucial for patient management and antibiotic stewardship Unyvero detected bacterial pathogens up to 7 days earlier and would have enabled prompt and appropriate targeted antibiotics in 41.3% of cases and reduced time to appropriate therapy by 25.7 hours

• OpGen Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  3/25/2021

  Total combined pro-forma revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.4 million cash as of December 31, 2020    Raised an additional $34.7 million of capital in the first quarter of 2021                Conference call to be held at 4:30 p.m. Eastern Time today

• OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020

  3/11/2021

  OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Thursday, March 25, 2021.

• OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia

  3/8/2021

  OpGen today announced the release of a new peer-reviewed publication that demonstrates that the Unyvero Hospitalized Pneumonia (HPN) panel is a reliable and rapid diagnostic test with high negative predictive value for the detection of bacterial pathogens directly from native lower respiratory tract samples, allowing identification of bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.

• OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System

  3/1/2021

  Chinese regulatory authority NMPA completes registration of Unyvero instrument system as IVD for Chinese market Application of Unyvero cartridge for pneumonia is under review and pending NMPA approval OpGen’s subsidiary Curetis and its Chinese partner Beijing Clear Biotech continue working with the NMPA towards approval of pneumonia test in China

• OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update

  1/13/2021

  Preliminary total pro-forma combined revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.3 million cash as of December 31, 2020 and total capital raised in 2020 of $35.3 million OpGen subsidiary Ares Genetics to explore multiple collaboration opportunities with several parties

• OpGen Subsidiary Curetis and Annar Enter into Unyvero Distribution Partnership for Colombia

  1/5/2021

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that its subsidiary Curetis GmbH has entered into a distribution agreement with Annar Health Technologies for Colombia.

• Results from 1,400 Patient Sample Multicenter Study Published: Unyvero LRT BAL Panel Provides Accurate Detection in Bronchoalveolar Lavage Fluid, Allowing Enhanced Diagnosis of Lower Respiratory Tract Infections

  12/17/2020

  Early diagnosis and proper choice of antimicrobials are crucial for successful management of pneumonia Study demonstrates Unyvero LRT BAL provides accurate detection of common agents of bacterial pneumonia and of Pneumocystis jirovecii in ~4.5 hours Performance data, comprehensive coverage and fast time to result of this panel suggest significant clinical value for choosing appropriate antibiotics and for antibiotic stewardship

• OpGen Announces Planned Leadership Transition at Next Generation Sequencing and Bioinformatics Subsidiary Ares Genetics

  12/9/2020

  Dr. Andreas Posch, while stepping down as Managing Director and CEO to pursue new opportunities, remains on board throughout 2021 as special advisor to facilitate smooth transition

• OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects Granting of Key Patent

  12/1/2020

  Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing

• OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Testing Service for Native Specimens and Receives Bulk Order from Public Health Agency

  11/12/2020

  Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens

• OpGen to Provide Business Update and Financial Results for the Third Quarter 2020

  10/29/2020

  OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 11, 2020. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities. C

• OpGen Provides Business and Pipeline Update and Announces Preliminary Unaudited Revenue and Cash Position for the Third Quarter 2020

  10/15/2020

  OpGen takes strategic steps to expand the Unyvero platform and product pipeline , to focus on the pending Acuitas AMR Gene Panel (isolates) FDA clearance and expects to invest significantly in bioinformatics OpGen subsidiary Ares Genetics received notification of exercise of option to negotiate for a potential future license by its IVD Partner OpGen to d iscontinue Acuitas AMR Gene Panel (urine) clinical trial and discontinue FISH product line globally by

• OpGen Issues Formal Response to FDA’s Requests for Additional Information and Expects Near Term FDA Clearance Decision for Acuitas AMR Gene Panel

  10/13/2020

  OpGen’s Acuitas AMR Gene Panel allows testing for a very comprehensive panel of more than 40 diagnostic targets (pathogens and genetic AMR markers) in pure bacterial colonies

• OpGen Group Company Ares Genetics Wins Austrian Digitization Award for ares-genetics.cloud

  10/5/2020

  Ares Genetics wins Austrian Digitization Award for Digital Products and Solutions ares-genetics.cloud for AI-powered Antibiotic Resistance Prediction awarded by Federal Ministry for Digital and Economic Affairs VIENNA, Austria, and GAITHERSBURG, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has won the Austrian Digitization Award. Ares Genetics has been selected by an

• OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators

  9/30/2020

  Project: AI based Assay Development for carbapenem-resistance based on porin loss and efflux pump overexpression in G ram-negative bacteria Project is part of the Research Campus Infecto G nostics and includes project partners at the University Hospital Jena, Institute for Infectious Diseases and Infection Contro l GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Sept. 30, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the pow

• OpGen Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in COVID-19 Pneumonia Patients and Presents Data on Unyvero HPN Panel at ECCVID 2020

  9/28/2020

  Rapid and accurate detection is essential to assess bacterial pneumonia co-infection in CO VID-19 critically ill patients Unyvero HPN panel demonstrated high negative predictive value (99.8% ) with potentially high clinical utility as rapid rule - out Unyvero reduces diagnostic turnaround times from days to less than 5 hours ; HPN panel viewed as a useful diagnostic tool to help with early detection  and antimicrobial stewardship GAITHERSBURG, Md. and HOLZG

• Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing

  9/16/2020

  Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance Presented Study on Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results Work Aimed at Demonstrating Diagnostic Value of Next-Generation Sequencing for Antimicrobial Susceptibility Testing and Translation into Clinical Practice VIENNA, Austria and GAITHERSBURG, Md., Sept. 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today t

• OpGen Group Company Ares Genetics Nominated for Austrian Innovation Award for AI-powered Molecular Antibiotic Susceptibility Test

  9/8/2020

  OpGen, Inc., announced that its subsidiary Ares Genetics GmbH has been nominated for the 40th Austrian Innovation Award.